Transparency Reporting for 2022

Bayer is committed to fostering transparency in its dealings with health care professionals and organizations. This is in order to support building trusted relationships between our organization and the communities we serve.

Transparency directly aligns with our corporate value of Integrity, and we continue to strive to ensure that the pharmaceutical industry communicates with openness where we do business.

In Canada, the voluntary disclosure framework was developed by Innovative Medicines Canada, an organization of which Bayer is a member. As a member of this organization, Bayer works to ensure that companies like ours act with a high degree of transparency and ethical standards.

Bayer Canada regularly interacts with and invests into the Canadian health care system. We consult with Canadian healthcare professionals (HCPs) and others in the scientific community as part of our product development. We provide grants and sponsorships to healthcare organizations (HCOs) primarily for scientific purposes. We may also sponsor HCPs to attend international congresses for scientific exchange to benefit Canadians.

We are proud of the support we provide to the healthcare industry for ongoing medical education and other permitted activities. 

Data:

From January 1, 2022 to December 31, 2022, we are presenting the aggregate total of investment into the Canadian system in the following three categories:

 

  • Fee for HCP services: $4,899,357
  • Funding to HCOs: $8,484,386
  • Sponsorship of Scientific Exchange: $327,319



Explanatory Notes:

•    Wherever our transparency systems capture this information, applicable taxes are included.
•    Wherever our transparency systems capture this information, incidental expenses are included (for example parking and mileage).
•    Funding for HCOs excludes Bayer’s R&D activities
•    Transfers of value are captured according to the payment date, and not necessarily the date when the activity occurred.

Note: While Bayer makes every effort to present accurate and reliable information, Bayer makes no warranty and assumes no legal liability or responsibility for the accuracy or completeness of the information contained herein. Bayer shall not be liable for damages resulting from the use or misuse of the information contained on this website. Certain links may lead to resources located on servers that are not maintained by Bayer or under its control, and such hypertext links are provided as a convenience only. The inclusion of a link does not imply endorsement by or of the referenced site and Bayer is not responsible for the contents of or the availability of access to such websites.